CANF - Can-Fite BioPharma Ltd.

NYSE American - NYSE American Delayed Price. Currency in USD

Can-Fite BioPharma Ltd.

10 Bareket Street
Kiryat Matalon PO Box 7537
Petah-Tikva 4951778
972 3 924 1114

Full Time Employees7

Key Executives

NameTitlePayExercisedYear Born
Prof. Pnina FishmanScientific Founder, CEO & DirectorN/AN/A1948
Mr. Motti FarbsteinChief Operating & Financial OfficerN/AN/A1964
Dr. Ilan CohnCo-Founder & ChairmanN/AN/A1954
Dr. Vibeke Strand M.D., FACP, FACR (USA)Sr. Clinical AdvisorN/AN/AN/A
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver and inflammatory disease, and sexual dysfunction. The company's lead drug candidate CF101 (Piclidenoson), which is in Phase III clinical trial for the treatment of rheumatoid arthritis and psoriasis. It also develops CF102 (Namodenoson) that is completed Phase II clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase II trial for the treatment of non-alcoholic steatohepatitis (NASH); and CF602, which is in pre-clinical trial for the treatment of sexual dysfunction. Can-Fite BioPharma Ltd. has a license, collaboration, and distribution agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was founded in 1994 and is headquartered in Petah-Tikva, Israel.

Corporate Governance

Can-Fite BioPharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.